Medpace Holdings, Inc. · NASDAQ:MEDP
Medpace — Q2 2026 Earnings Presentation
15 slides from Medpace's earnings presentation, Jul 23, 2026
Slide 1: Q2 2026 Financial Results
Q2 2026 FINANCIAL RESULTS JULY 22, 2026
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of histori
Slide 3: Q2 2026 – Key Operating Highlights
Q2 2026 – KEY OPERATING HIGHLIGHTS ($ in millions) Second Quarter Year-to-Date 2026 2025 % Change 2026 2025 % Change Revenue, net $ 707.3 $ 603.3 17.2 % $ 1,413.9 $ 1,161.9 21.7 % Net New Business Awards $ 795.7 $ 620.5 28.2 % $ 1,414.2 $ 1,120.6 26.2 % Net Book-to-Bill (A) 1.13 1.03 n.m. 1.00 0.96
Slide 4: Backlog and New Award Trends
BACKLOG AND NEW AWARD TRENDS Net Book-to-Bill Backlog Conversion Rate Net New Business Awards Ending Backlog and Est. NTM Backlog Conversion(A) (A) Represents estimated midpoint of NTM conversion(A) ($ in millions) A. Amount of backlog estimated to convert to revenue in the next twelve months. 4 MAK
Slide 5: Q2 2026 – Key Financial Highlights
Q2 2026 – KEY FINANCIAL HIGHLIGHTS ($ in millions, except per share data) Second Quarter Year-to-Date 2026 2025 % Change(B) 2026 2025 % Change(B) Revenue, net $ 707.3 $ 603.3 17.2 % $ 1,413.9 $ 1,161.9 21.7 % EBITDA(A) $ 153.4 $ 130.5 17.6 % $ 302.8 $ 249.1 21.5 % % Margin 21.7 % 21.6 % n.m. 21.4 %
Slide 6: Key Financial Trends
KEY FINANCIAL TRENDS ($ in millions) ($ in millions) Revenue, net EBITDA(A) Represents percent of Revenue ($ in millions) Net Income Net Income per diluted share A. See the appendix for the non-GAAP reconciliation of the EBITDA calculations. 6 MAKING THE COMPLEX SEAMLESS
Slide 7: Key Financial Trends
KEY FINANCIAL TRENDS ($ in millions) Revenue +10.9% - 14.0% YOY +20.0% YOY +11.8% YOY +29.2% YOY +27.8% YOY Guidance Range $2,805 - $2,885 ($ in millions) EBITDA(A) +10.8% - 15.1% YOY +16.1% YOY +32.5% YOY +17.7% YOY Guidance Range +38.1% YOY $618 - $642 A. See the appendix for the non-GAAP reconcil
Slide 8: Key Financial Trends
KEY FINANCIAL TRENDS ($ in millions) Net Income +9.5% - 13.9% YOY +11.6% YOY +43.0% YOY +15.3% YOY +34.9% YOY Guidance Range $494 - $514 Net Income per diluted share +12.9% - 17.5% YOY +21.0% YOY +42.2% YOY +22.0% YOY +51.4% YOY Guidance Range $17.25 - $17.95 8 MAKING THE COMPLEX SEAMLESS
Slide 9: Revenue Composition
REVENUE COMPOSITION Therapeutic Area Customer Tier Top 10 Customer Concentration Concentration(B) Concentration (A) Large Mid-sized Pharma Biopharma Top 5 Q2 2026 LTM Small All Other Biopharma Rest of Top 10 (A) Mid-sized Large Top 5 Biopharma Pharma Q2 2025 LTM Rest of Top 10 Small All Other Biopha
Slide 10: Q2 2026 – Cash Position
Q2 2026 – CASH POSITION ($ in millions) ($ in millions) Second Quarter Year-to-Date Free Cash Flow and Free Cash Flow Conversion(A) Free Cash Flow 2026 2025 2026 2025 (A) Operating Cash Flow $ 162.0 $ 148.5 $ 313.8 $ 274.4 (GAAP) Less: CAPEX 23.9 6.1 30.7 16.1 Free Cash Flow $ 138.1 $ 142.4 $ 283.1
Slide 11: Full Year 2026 Guidance
FULL YEAR 2026 GUIDANCE ($ in millions, except per share data) As of April 22, 2026 As of July 22, 2026 Guidance Range Growth Rate Guidance Range Growth Rate Revenue, net $2,755.0 - $2,855.0 8.9% - 12.8% $2,805.0 - $2,885.0 10.9% - 14.0% EBITDA $605.0 - $635.0 8.5% - 13.9% $618.0 - $642.0 10.8% - 15
Slide 12: Appendix
APPENDIX nhseatl
Slide 13: Q2 2026 – Income Statement
Q2 2026 – INCOME STATEMENT % % Revenue, Revenue, 2Q26 vs. 2Q25 ($ in millions, except per share amounts) 2Q26 net 2Q25 net $ Change % Change Revenue, net $ 707.3 100.0 % $ 603.3 100.0 % $ 104.0 17.2 % Operating expenses: Direct service costs, excluding depreciation and amortization 202.6 28.6 % 185.
Slide 14: EBITDA Reconciliation
EBITDA RECONCILIATION YTD YTD ($ in millions) 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 2025 2026 Net income as reported (GAAP) $ 96.4 $117.0 $114.6 $ 90.3 $111.1 $135.1 $123.9 $121.4 $ 204.9 $ 245.2 Income tax provision 22.4 16.9 3.6 34.3 31.7 21.7 23.7 30.3 37.9 54.0 Interest income, net (7.5) (7.9)
Slide 15: FY2026 Guidance Reconciliation
FY2026 GUIDANCE RECONCILIATION ($ in millions, except per share amounts) Net Income per diluted Net Income share Low High Low High Net income and net income per diluted share (GAAP) $ 494.0 $ 514.0 $ 17.25 $ 17.95 Income tax provision 117.4 121.4 Interest income, net (21.1) (21.1) Depreciation 27.1